Sector News

Boehringer charges ahead with sale of U.S. generics biz with bids from Hikma, Mallinckrodt

June 30, 2015
Life sciences
Earlier this year, Boehringer Ingelheim said it was considering selling its U.S.-based generics business for up to €2 billion ($2.2 billion) to focus on branded meds. Now, Hikma Pharmaceuticals, Mallinckrodt and Perrigo are approaching the bidding table, Bloomberg reports.
 
Boehringer is considering swapping assets or selling its Roxane Labs unit, with Hikma, Mallinckrodt and Perrigo reportedly laying down proposals. A decision on the winner could be made within weeks, but the German drugmaker may still choose to hold onto the business, sources told the news outlet. While Boehringer would prefer an asset swap, that type of deal may prove more difficult than selling the business outright, they added.
 
In January, Boehringer said it had tapped Morgan Stanley to explore its options for the Columbus, OH-based Roxane Labs, but had not decided whether to move forward with a sale, company spokeswoman Kathy Vincent told FiercePharma at the time. The unit, which develops and markets Boehringer’s generic drugs and boasts about 1,300 employees, has a better track record with regulators than Ben Venue Laboratories, the troubled injectables business that Boehringer unloaded to Hikma last year. And there “may be other strategic options that can better support the already successful Roxane Labs business and its significant future potential,” Vincent said at the time.
 
Still, the company started approaching interested buyers for Roxane in April, a company spokeswoman told Bloomberg. Hikma, Perrigo and Mallinckrodt declined to comment on a potential deal.
 
A deal for Roxane Labs could mean big things for Hikma, as it looks to broaden its portfolio and build on its previous relationship with Boehringer. Last year, the Jordan-based drugmaker shelled out $300 million in cash and performance-related milestones to snag assets and injectable products from the Ben Venue unit. Hikma also bought a troubled Ben Venue plant in a separate deal, but has since gutted the facility and used the equipment in other plants.
 
Snatching up Roxane Labs could also help Mallinckrodt, Jeffries analyst Anthony Petrone said in a note to clients. Mallinckrodt is trying to bulk up in generics, and Roxane brings a portfolio of 200 oral, liquid, topical and nasal generic products to the table. And although the two have some overlap in offerings, Roxane would hand Mallinckrodt “several key products” including generic Flonase and generic oral Suboxone, Petrone said.
 
By Emily Wasserman
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach